MSB 7.69% $1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-519

  1. 151 Posts.
    lightbulb Created with Sketch. 96
    https://www.youtube.com/watch?v=43XAc5iDN9k

    If anyone is interested, this is a recent 40 minute conversation between Dr Howard Bauchner from JAMA and Dr Peter Marks, the director of Centre for Biologicals Evaluation and Research (CBER) at FDA, talking about process for Vaccine evaluation, but essentially going through in detail differences, communication and processes for biologics EUA and BLA’s.
    in detail
    very interesting
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.